AFM-24
- Generic Name
- AFM-24
Affimed Advances in Innate Cell Engager Therapies for Cancer Treatment
Affimed, a leader in innate cell engager (ICE®) therapies, is making significant strides in the clinical development of novel treatments for solid and hematologic tumors. With over 500 patients treated, the company has demonstrated clinical efficacy across various indications, leveraging its proprietary IP targeting CD16A on NK cells and macrophages. Affimed's ongoing clinical programs, including AFM24, Acimtamig (AFM13), and AFM28, show promising results in treating advanced/metastatic NSCLC, R/R Classical HL, and R/R CD123+ AML, respectively. The company's innovative approach combines ICE® molecules with NK cell therapy and checkpoint inhibitors to enhance the immune system's ability to fight cancer.
AFM24/Atezolizumab Combination Shows Promise in Heavily Pretreated NSCLC
• Affimed's AFM24 combined with atezolizumab demonstrates meaningful clinical activity in heavily pretreated non-small cell lung cancer (NSCLC) patients, including those with EGFR mutations.
• In EGFR mutant NSCLC patients, the combination therapy achieved an overall response rate (ORR) of 24% and a disease control rate (DCR) of 71%.
• For EGFR wild-type NSCLC patients, the combination showed an ORR of 21% and a DCR of 76%, with a preliminary median progression-free survival (PFS) of 5.6 months.
• A post-hoc analysis suggests that higher doses of AFM24 (720 mg weekly) may lead to improved efficacy, prompting its use in future development programs.
NK Cell Therapy Pipeline Shows Promise with Over 160 Therapies in Development
• The NK cell therapy field is experiencing significant growth, driven by its potential to address unmet needs in cancer treatment with safer, more targeted options.
• Over 140 companies are actively involved in developing more than 160 NK cell therapies, indicating robust R&D investment and confidence in this therapeutic area.
• Clinical trials are progressing for various NK cell therapies, including CAR-NK cell therapies and those targeting autoimmune disorders, showcasing versatility.
• Regulatory support, such as FDA orphan drug designation and fast track designation, is facilitating the development and potential approval of NK cell therapies.
Affimed N.V. Advances in Clinical Development of Novel Therapies for Solid and Liquid Tumors
Affimed N.V., a leader in innate cell engager (ICE®) technology, is making significant strides in the clinical development of novel therapies targeting solid and liquid tumors. With over 500 patients treated, the company has demonstrated clinical efficacy across various indications, leveraging its proprietary IP targeting CD16A on NK cells and macrophages. Affimed's pipeline includes promising candidates like AFM24, AFM13, and AFM28, each showing potential in addressing significant unmet needs in cancer treatment, particularly in non-small cell lung cancer (NSCLC), Hodgkin lymphoma (HL), and acute myeloid leukemia (AML).
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath